In the last trading session, 1.67 million Autolus Therapeutics plc ADR (NASDAQ:AUTL) shares changed hands as the company’s beta touched 1.67. With the company’s per share price at $4.45 changed hands at $0.1 or 2.30% during last session, the market valuation stood at $774.03M. AUTL’s last price was a premium, traded about 1.35% off its 52-week high of $4.39. The share price had its 52-week low at $1.60, which suggests the last value was 64.04% up since then. When we look at Autolus Therapeutics plc ADR’s average trading volume, we note the 10-day average is 1.02 million shares, with the 3-month average coming to 484.09K.
Analysts gave the Autolus Therapeutics plc ADR (AUTL) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended AUTL as a Hold, 8 felt it is a Buy and 0 rated the stock as Underweight. Autolus Therapeutics plc ADR’s EPS for the current quarter is expected to be -$0.25.
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Instantly AUTL was in green as seen at the end of in last trading. With action 29.74%, the performance over the past five days has been green. The jump to weekly highs of 4.46 on Friday, 11/17/23 added 2.30% to the stock’s daily price. The company’s shares are showing year-to-date upside of 134.21%, with the 5-day performance at 29.74% in the green. However, in the 30-day time frame, Autolus Therapeutics plc ADR (NASDAQ:AUTL) is 78.00% up. Looking at the short shares, we see there were 1.42 million shares sold at short interest cover period of 4.82 days.
The consensus price target for the stock as assigned by Wall Street analysts is $8.80, meaning bulls need an upside of 49.43% from its current market value. According to analyst projections, AUTL’s forecast low is $3.20 with $12.00 as the target high. To hit the forecast high, the stock’s price needs a -169.66% plunge from its current level, while the stock would need to tank 28.09% for it to hit the projected low.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
Data shows that the Autolus Therapeutics plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 51.36% over the past 6 months, a 36.94% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Autolus Therapeutics plc ADR will fall -8.70%, while the growth in revenue is estimated to hit -8.70% for the next quarter. Year-over-year growth is forecast to reach -69.50% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $300k. 2 analysts are of the opinion that Autolus Therapeutics plc ADR’s revenue for the quarter ending Mar 2024 will be $750k. The company’s revenue for the corresponding quarters a year ago was $3.83 million and $1.29 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -92.20%. The estimates for the next quarter sales put growth at -42.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -26.10%. The 2023 estimates are for Autolus Therapeutics plc ADR earnings to increase by 31.27%.
Autolus Therapeutics plc ADR is expected to release its next quarterly earnings report on November 02.
Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.45% of Autolus Therapeutics plc ADR shares while 81.60% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 89.13%. There are 81.60% institutions holding the Autolus Therapeutics plc ADR stock share, with Syncona Portfolio Ltd the top institutional holder. As of Jun 29, 2023, the company held 12.29% of the shares, roughly 21.35 million AUTL shares worth $50.81 million.
Blackstone Inc holds the second largest percentage of outstanding shares, with 11.79% or 20.49 million shares worth $48.76 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Aug 30, 2023 were iShares NASDAQ Biotechnology ETF and Harbor Disruptive Innovation Fund. With 0.84 million shares estimated at $2.69 million under it, the former controlled 0.48% of total outstanding shares. On the other hand, Harbor Disruptive Innovation Fund held about 0.10% of the shares, roughly 0.18 million shares worth around $0.57 million.